Research progress in programmed cell death protein ligand-1 targeting peptide-based radionuclide-labeled molecular probes

Shiyu Zhu; Beibei Liang; Jiayu FU; Jianguo Lin; Ling Qiu

Return

Research progress in programmed cell death protein ligand-1 targeting peptide-based radionuclide-labeled molecular probes

VernacularTitle:靶向程序性细胞死亡蛋白配体-1多肽类放射性核素标记分子探针研究进展
Author: Shiyu ZHU ^{1
,

2} ; Beibei LIANG ; Jiayu FU ; Jianguo LIN ; Ling QIU
Author Information

1. 南京医科大学药学院,江苏南京 211166
2. 江苏省原子医学研究所江苏省分子核医学重点实验室,江苏无锡 214063
Keywords: programmed cell death protein ligand-1; peptide-based molecular probe; positron emission computed tomo-graphy; single-photon emission computed tomography
From: Journal of Xinxiang Medical College 2024;41(5):491-496
CountryChina
Language:Chinese
Abstract: Programmed cell death protein ligand-1(PD-L1)is an important immune checkpoint molecule that plays an important role in regulating the body's immune response.Several clinical studies have shown that the expression level of PD-L1 in tumors is closely related to the efficacy of immune checkpoint inhibitors.Due to the spatial and temporal heterogeneity of tumors,immunohistochemical methods commonly used in clinical practice cannot accurately and comprehensively reflect the ex-pression level of PD-L1 in patients.Given that nuclear-medicine molecular imaging technology can noninvasively,real-time,dy-namically and visually monitor the expression level of PD-L1 in vivo at the molecular level,this article mainly focuses on the re-search of peptide-based radiolabeled molecular probes targeting PD-L1,with the aim of providing guidance for the search of no-vel peptide molecular probes for immunoimaging as well as for the screening of immunotherapy-suitable patients and evaluation of therapeutic efficacy,and other clinical applications.